Matthew Carraro

Statistics

Publications

Citations

166

H-Index

Active since

2017

Affiliations

Novant Health(Current)

OhioHealth

Massachusetts College of Pharmacy and Health Sciences

Biogen (United States)

Cleveland Clinic

Matthew Carraro is an author at Novant Health specializing in multiple sclerosis, relapsing-remitting multiple sclerosis treatment, and multiple sclerosis therapy.

Publications per year

2017–2020

Publications

Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US

Daniel Ontaneda, Jacqueline Nicholas, Matthew Carraro et al. · Multiple Sclerosis and Related Disorders · 2018 · 58 citations

Pharmacy, Pharmacotherapy, Clinical Pharmacology +16

Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223

Brian Steingo, Yaser Al Malik, Ann Bass et al. · Journal of Neurology · 2020 · 53 citations · Full text

Medicine, Neurology, Pharmacology +14

Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab

Heinz Wiendl, Matthew Carraro, Guillermo Izquierdo et al. · Neurology Neuroimmunology & Neuroinflammation · 2019 · 42 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Development of an Algorithm to Identify Multiple Sclerosis (MS) Disease Severity Based on Healthcare Costs in a US Administrative Claims Database (P2.052)

Jacqueline Nicholas, Daniel Ontaneda, Matthew Carraro et al. · Neurology · 2017 · 13 citations

Pharmacy, Pharmacoeconomics, Clinical Decision Support +16

1–4 of 4